Early efficacy and safety of anti–T-lymphocyte globulin (ATLG) induction therapy in renal transplant recipients in China: A multicenter, prospective observational study
Early efficacy and safety of anti–T-lymphocyte globulin (ATLG) induction therapy in renal transplant recipients in China: A multicenter, prospective observational study. // Transplant Immunology. – URL: https://www.sciencedirect.com/science/article/pii/S0966327426001334?dgcid=rss_sd_all
Early efficacy and safety of anti–T-lymphocyte globulin (ATLG) induction therapy in renal transplant recipients in China: A multicenter, prospective observational study. Transplant Immunology. https://www.sciencedirect.com/science/article/pii/S0966327426001334?dgcid=rss_sd_all
“Early efficacy and safety of anti–T-lymphocyte globulin (ATLG) induction therapy in renal transplant recipients in China: A multicenter, prospective observational study.” Transplant Immunology.
@article{article119722,
title = {Early efficacy and safety of anti–T-lymphocyte globulin (ATLG) induction therapy in renal transplant recipients in China: A multicenter, prospective observational study},
journal = {Transplant Immunology},
url = {https://www.sciencedirect.com/science/article/pii/S0966327426001334?dgcid=rss_sd_all}
}